The Role of Immunotherapy as Bladder-Sparing Solution for Muscle-Invasive and Non-muscle-Invasive Bladder Cancer: Current Status and Future Perspectives

2022 ◽  
pp. 109-122
Author(s):  
Giuseppe Basile ◽  
Giovanni Enrico Cacciamani ◽  
Simone Scuderi ◽  
Francesco Barletta ◽  
Vito Cucchiara ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Current Status ◽  
Future Perspectives ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive ◽  
Bladder Sparing

scholarly journals Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives

2021 ◽  
Vol 22 (13) ◽  
pp. 7201
Author(s):  
In-Ho Kim ◽  
Hyo-Jin Lee
Keyword(s):  
Bladder Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Systemic Treatment ◽  
Checkpoint Inhibitors ◽  
Invasive Bladder Cancer ◽  
Current Evidence ◽  
Future Perspectives ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Radical cystectomy is the primary treatment for muscle-invasive bladder cancer; however, approximately 50% of patients develop metastatic disease within 2 years of diagnosis, which results in dismal prognosis. Therefore, systemic treatment is important to improve the prognosis of muscle-invasive bladder cancer. Currently, several guidelines recommend cisplatin-based neoadjuvant chemotherapy before radical cystectomy, and adjuvant chemotherapy is recommended in patients who have not received neoadjuvant chemotherapy. Immune checkpoint inhibitors have recently become the standard treatment option for metastatic urothelial carcinoma. Owing to their clinical benefits, several immune checkpoint inhibitors, with or without other agents (including other immunotherapy, cytotoxic chemotherapy, and emerging agents such as antibody drug conjugates), are being extensively investigated in perioperative settings. Several studies for perioperative immunotherapy have shown that immune checkpoint inhibitors have promising efficacy with relatively low toxicity, and have explored the predictive molecular biomarkers. Herein, we review the current evidence and discuss the future perspectives of perioperative systemic treatment for muscle-invasive bladder cancer.

scholarly journals The Role of EGFR Family Inhibitors in Muscle Invasive Bladder Cancer: A Review of Clinical Data and Molecular Evidence

2015 ◽  
Vol 193 (1) ◽  
pp. 19-29 ◽  
Author(s):  
Benjamin A. Mooso ◽  
Ruth L. Vinall ◽  
Maria Mudryj ◽  
Stanley A. Yap ◽  
Ralph W. deVere White ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Data ◽  
Invasive Bladder Cancer ◽  
Molecular Evidence ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive ◽  
Egfr Family

The role of device assisted techniques in BCG non-responder non-muscle invasive bladder cancer

2019 ◽  
Vol 18 (9) ◽  
pp. e3247-e3248
Author(s):  
M. Ragonese ◽  
L. Di Gianfrancesco ◽  
G. Palermo ◽  
C. Gandi ◽  
E. Sacco ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document